LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and preclinical pharmacology highlights for AVA6103, a PDC comprised of the pre|CISION® peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform.Details for Avacta’s poster presentations are below and can be found on the AACR website:Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavageSession Category : Experimental and Molecular Therapeutics: Experimental and Molecular Therapeutics Session Title: Therapeutic Approach to Attack the Tumor MicroenvironmentTherapeutic Approach to Attack the Tumor Microenvironment Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CTAbstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insightsSession Category : Tumor Biology: Tumor Biology Session Title : Targeting the Tumor Microenvironment: A Brave New World: Targeting the Tumor Microenvironment: A Brave New World Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CTAbstract Number and Title: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugatesSession Title : First-in-Human Phase I Clinical Trials 2: First-in-Human Phase I Clinical Trials 2 Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CTFor further information from Avacta, please contact:Avacta Group plcMichael Vinegrad, Group CommunicationsDirector www.avacta.com Peel Hunt (Nomad and Broker)James Steel / Chris Goldenwww.peelhunt.com Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers www.panmureliberum.com ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie [email protected] ContactRenee LeckTHRUST Strategic Communications [email protected] Media ContactCarly ScadutoCarly Scaduto [email protected] Avacta - www.avacta.comAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform

Former Barclays boss Bob Diamond's City broker Panmure Gordon has agreed to merge with rival Liberum, with fellow former Barclays executive Rich Ricci hired to head up the new firm.